Plain-English translation of NCT07154563 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging technology called an ICG-CK fluorescent probe that doctors use during breast cancer surgery to quickly detect whether cancer has spread to the sentinel lymph nodes (the first lymph nodes cancer typically spreads to). The probe glows under special imaging equipment, making it easier for surgeons to spot cancer cells right away instead of waiting for lab results.
Currently, doctors have to wait hours or days for lab results to know if cancer has spread to lymph nodes during surgery. This new imaging method could give doctors an answer in minutes, helping them make faster treatment decisions and potentially improve outcomes for breast cancer patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, your sentinel lymph nodes will be removed during your breast cancer surgery as planned. The removed lymph nodes will then be treated with the new fluorescent probe and scanned using a special imaging system in the operating room to check for cancer cells. The results will be compared to traditional lab tests to see how well the new imaging method works.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Collaborators
Xiang'an Hospital of Xiamen University
Enrollment target
~60 participants
Started
February 2025
Primary completion
December 2026
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Junhong Chen, Postgraduate
Yunnan Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.